Open Access

Gene therapy of renal cancer using recombinant adeno‑associated virus encoding human endostatin

  • Authors:
    • Erlin Sun
    • Ruifa Han
    • Bingxin Lu
  • View Affiliations

  • Published online on: June 28, 2018     https://doi.org/10.3892/ol.2018.9036
  • Pages: 2789-2796
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Renal cell carcinoma (RCC) is characterized by robust angiogenesis during tumor development. Various therapies are not able completely eradicated tumor relapse. The present study targeted angiogenesis and developed a recombinant adeno‑associated virus (rAAV) vector containing human endostatin gene for human kidney cancer gene therapy. Prophylactic and therapeutic RCC models were established in nude mice by subcutaneous inoculation of RCC cells and intra‑muscular or intra‑tumor injection of rAAV‑Endostatin. The growth of xenograft tumors was evaluated by tumor volume and weight. The microvessel density (MVD) was used to measure the anti‑angiogenesis effect of rAAV‑Endostatin. The toxic effect of rAAV‑Endostatin was also examined. In the therapeutic model, tumor‑bearing mice with rAAV‑Endostatin intra‑tumor injection demonstrated slow tumor growth (32.63±9.75) compared with control groups with intratumoral rAAV‑enhanced yellow florescent protein (EYFP) injections (21.50±11.42) and the RPMI‑1640 group (21.75±10.48 days, for tumors to reach ~300 mm3). MVD of the xenografts treated with rAAV‑Endostatin was 8.30±3.14/0.739 mm2 whereas that of control groups was 13.87±4.09/0.739 mm2 (rAVV‑EYFP) and 13.76±3.50/0.739 mm2 (RPMI‑1640). No significant side effects associated with rAAV‑endostatin use were identified in the vital organs. rAAV‑Endostatin demonstrated significant anti‑angiogenesis and antitumor activities. It may serve as an effective agent for renal cancer gene therapy.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sun E, Han R and Lu B: Gene therapy of renal cancer using recombinant adeno‑associated virus encoding human endostatin. Oncol Lett 16: 2789-2796, 2018.
APA
Sun, E., Han, R., & Lu, B. (2018). Gene therapy of renal cancer using recombinant adeno‑associated virus encoding human endostatin. Oncology Letters, 16, 2789-2796. https://doi.org/10.3892/ol.2018.9036
MLA
Sun, E., Han, R., Lu, B."Gene therapy of renal cancer using recombinant adeno‑associated virus encoding human endostatin". Oncology Letters 16.3 (2018): 2789-2796.
Chicago
Sun, E., Han, R., Lu, B."Gene therapy of renal cancer using recombinant adeno‑associated virus encoding human endostatin". Oncology Letters 16, no. 3 (2018): 2789-2796. https://doi.org/10.3892/ol.2018.9036